Characterization and clinical implications of CpG island methylator phenotypes of resistant tumors

Key Points

• The aim is to identify DNA methylation subtypes in resistant tumors to better inform clinical decisions.
• Characterization of methylation patterns in resistant tumor samples
• Analysis of clinical data for prognosis and therapy selection
• Stratification of tumors based on identified methylation subtypes
• Identification of distinct CpG island methylator phenotypes
• Enhanced ability to predict treatment responses
• Potential for improved patient stratification and personalized therapy approaches